Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the system.
That’s the uncomfortable truth behind drug patents in Eurasia—and it’s why the stakes are higher than most teams realize until it’s…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Pharmaceutical patent strategy is often discussed like a binary choice: cut losses or keep fighting.
But the real question isn’t whether a patent is “good” or “bad.” It’s whether your portfolio is built to win—or whether it’s quietly turning into an ex…
The clock is ticking—and commercial market access vendors know it.
In pharma, timing isn’t just a scheduling detail. It’s a competitive weapon. The window between “launch” and “loss of exclusivity” can be measured in months, not years—and for commerc…
Before You Launch: The Freedom-to-Operate Checklist Pharma Teams Can’t Afford to Skip
In pharma, speed is a competitive advantage—until it isn’t.
A launch timeline that looks “on track” can collapse in a matter of weeks when a Freedom to Operate (FTO) …
Pharma procurement teams are sitting on a quiet risk radar—and most of them never turn it on.
Paragraph IV filings are often treated like a legal event: something for counsel to track, something for business development to react to, something for finan…
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore Read Post »
Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting a deal, or forecasting exclusivity value in Asia-Pacific, here’s the uncomfortable truth: “patent term” is n…
Drug patent expiry dates aren’t just legal milestones—they’re commercial clocks. And most life sciences teams treat them like a compliance checkbox instead of a revenue strategy. The result? Missed windows, delayed launches, and competitors who show up…
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
Sell the line—before the patent breaks.
In pharma manufacturing, timing isn’t a “nice-to-have.” It’s the difference between being a preferred supplier and being an afterthought.
As patents approach expiration, generic and biosimilar players don’t jus…
The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/
DrugChatter: How does lyrica affect liver function? Read Post »
The “Smarter Monopoly” Debate Is Here—And It’s Not Just Pharma Lobbying
For years, the pharmaceutical industry has lived under a familiar logic: patents reward innovation, exclusivity periods protect investment, and the market eventually opens up to ge…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Get new actionable insights and updates from BiotechBlog
